Pefloxacin


Full Generic Medicine Info
Dosage/Direction for Use

Oral
Susceptible infections
Adult: 400 mg bid.
Renal impairment: Dose reduction may be necessary.

Oral
Acute uncomplicated cystitis in women
Adult: 800 mg as single dose.
Renal impairment: Dose reduction may be necessary.

Oral
Gonococcal urethritis in men
Adult: 800 mg as single dose.
Renal impairment: Dose reduction may be necessary.
Administration
Should be taken with food.
Contraindications
Hypersensitivity to quinolones, children <12 yr, pregnancy, lactation.
Special Precautions
Underlying CNS disease; hepatic disease; renal impairment. Avoid sun exposure, may cause severe sunburn.
Adverse Reactions
Nausea, vomiting, gastric pain, dizziness, insomnia, allergic skin reactions, thrombocytopaenia, leukopenia/neutropenia, photosensitisation, arthropathy, muscular pain, headache, delusions, depression, hallucinations, hepatic dysfunction.
Drug Interactions
Reduced absorption with antacids, didanosine (DDI), iron salts, pirenzepine, sucralfate, vincristine, zinc salts; increased levels with cimetidine, probenecid, theophylline; increases the levels of cyclosporine; causes seizures with foscarnet, NSAIDs, piroxicam; hypoglycemia with glimeperide; antagonistic with quercetin.
Action
Pefloxacin is a fluoroquinolone antibacterial that exhibits its bactericidal action by inhibition of DNA gyrase and topoisomerase IV which are needed for bacterial DNA reproduction.
Metabolism: Extensive metabolism; converted to N-desmethylpefloxacin (norfloxacin).
Excretion: 8-13 hr (elimination half-life).
Storage
Oral: Store at room temperature. Keep away from excess heat and moisture.
CIMS Class
Quinolones
ATC Classification
J01MA03 - pefloxacin ; Belongs to the class of fluoroquinolones. Used in the systemic treatment of infections.
Disclaimer: This information is independently developed by CIMS based on pefloxacin from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2022 CIMS. All rights reserved. Powered by CIMSAsia.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in